CE: New Insulin/GLP-1RA Agents: Overview for the Pharmacist

Alysa Martin

Abstract


Diabetes is a rapidly growing disease that is progressive in nature. Many medications are approved for the treatment of diabetes however, several novel agents show improved efficacy and safety over current therapies. In late 2016, two novel diabetic agents became available, insulin glargine and lixisenatide and insulin degludec and liraglutide. These medications combine basal insulin and a glucagon-like peptide-1 receptor agonist and were approved by the FDA to improve glycemic control in patients with Type 2 Diabetes Mellitus. Both products have shown benefits to patients during clinical trials. This review will discuss characteristics of each agent and where the use of these drugs may be implemented into current treatment guidelines.

Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.